老虎证券

BUZZ-Viking Therapeutics' oral obesity drug meets mid-stage study goal, shares fall

Reuters
08/19
BUZZ-<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' oral obesity drug meets mid-stage study goal, shares fall

** Shares of drug developer Viking Therapeutics VKTX.O fall 18% to $33.96 premarket

** Co says its experimental oral obesity drug, VK2735, showed statistically significant reductions in body weight compared with placebo and was safe and well-tolerated through 13 weeks of daily dosing

** Co says the drug helped patients lose 12.2% of their body weight on average over 13 weeks

** Analysts ahead of the results had expected weight loss in the range of 10% to 15% on average and greater than the 8.2% seen in a small early-stage trial

** Co says 13% of participants receiving placebo discontinued treatment due to side effects, compared with 20% of participants receiving VK2735

** Up to last close, stock was up 4.6% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10